{"id":"mb-102-dmid","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD47 is a protein that inhibits phagocytosis, and by targeting it, MB-102 DMID aims to stimulate the immune system to attack cancer cells.","oneSentence":"MB-102 DMID is a monoclonal antibody targeting CD47.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:21.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05943977","phase":"PHASE3","title":"A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2023-03-02","conditions":"Kidney Diseases, Kidney Injury, Kidney Failure","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Relmapirazin"],"phase":"phase_3","status":"active","brandName":"MB-102 DMID","genericName":"MB-102 DMID","companyName":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","companyId":"hangzhou-zhongmei-huadong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MB-102 DMID is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}